Get the Stockscreener App
28.42
1,515%
26.66
Second Sight Medical Products, stock is traded at $28.42, with a volume of 1,412.
It is up +1,515% in the last 24 hours and up +1,515% over the past month.
Second Sight Medical Products, Inc., together with its subsidiaries, develops, manufactures, and markets prosthetic devices to restore functional vision of blind individuals in the United States, Canada, Europe, the Middle East, and Asia. It offers Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa. The company was formerly known as Second Sight LLC. and changed its name to Second Sight Medical Products, Inc. Second Sight Medical Products, Inc. was founded in 1998 and is headquartered in Sylmar, California.
See More
Previous Close:
$1.76
Open:
$28.55
24h Volume:
1,412
Relative Volume:
167.01
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-129.20
EPS:
-0.22
Net Cash Flow:
-
1W Performance:
+1,515%
1M Performance:
+1,515%
6M Performance:
+1,515%
1Y Performance:
+1,515%
1-Day Range:
$28.37
$28.55
1-Week Range:
$28.37
$28.55
52-Week Range:
$28.37
$28.55
Second Sight Medical Products, Stock (EYES) Company Profile
Name
Second Sight Medical Products,
Sector
Industry
Phone
818-833-5000
Address
12744 San Fernando Road, Suite 400, Sylmar
Compare EYES vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYES
Second Sight Medical Products,
|
28.42 | 0 | 0 | 0 | 0 | 0.00 |
ABT
Abbott Laboratories
|
102.61 | 176.41B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
92.13 | 116.35B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.12 | 105.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.34 | 62.29B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
88.26 | 48.63B | 6.30B | 1.07B | 1.09B | 1.8406 |
Second Sight Medical Products, Stock (EYES) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-19 | Initiated | Dougherty & Company | Buy |
| Jul-06-15 | Initiated | H.C. Wainwright | Buy |
Second Sight Medical Products, Stock (EYES) Latest News
Second Sight Medical Products Inc (VANIW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Second Sight Medical Products Inc (VANIW) Peer Comparison – Compare with Others - Value Research
Second Sight Medical Products Inc. Warrants (EYESW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Second Sight Medical Products Inc. Warrants (EYESW) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Second Sight Medical Products Inc. Warrants (EYESW) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Second Sight Medical Products Inc. (EYES) Peer Comparison – Compare with Others - Value Research
Second Sight Medical Products Inc (VANIW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Second Sight Medical Products Inc (VANIW) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
EU Clears PRIMA Retinal Chip for Commercial Sale After AMD Patient Reads 300-Page Novel - The Eastern Herald
Presenting on Emerging Growth Conference 94 Day 1 on July 15; Register to live stream - GlobeNewswire Inc.
ClearOne skyrockets from neurotech pivot, merger with Cortigent - Mugglehead Investment Magazine
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management - markets.businessinsider.com
Vivani Medical allows Novo Nordisk to evaluate NPM-139 - scanx.trade
ClearOne Merging With Cortigent - Pulse 2.0
Vivani to sell neurotech subsidiary Cortigent to ClearOne - MassDevice
ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical - Business Wire
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker - GlobeNewswire
Vivani Medical appoints August Moretti to board as Dr. Dean Baker retires - scanx.trade
Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention - markets.businessinsider.com
European Union Retinal Implant Electrode ArraysMarket Analysis, Forecast, Size, Trends and Insights - IndexBox
World Auditory Brainstem ImplantsMarket Analysis, Forecast, Size, Trends and Insights - IndexBox
Visual Prosthesis Market Size, Share, Growth, Forecast, 2034 - Straits Research
Vivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026 - markets.businessinsider.com
Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
Medical Bionic Implant and Artificial Organs Price in the European UnionMarket Insights - IndexBox
Stock List: Research Stocks from Around the World - GuruFocus
Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire
Single semaglutide implant showed >20% weight loss for a year - Stock Titan
Promising Six-Year Early Feasibility Study Results Released for the Orion System - Medical Product Outsourcing
Electroceuticals Market Size, Share & Growth Report, 2034 - Market Data Forecast
'Bionic Eye' Helps Man See After Decade of Impaired VisionABC News - ABC News - Breaking News, Latest News and Videos
Don’t Let Elon Musk Implant a Device in Your Skull - Home ❧ Current Affairs
Vivani Subsidiary Cortigent Presents Promising 6-Year Early - GlobeNewswire
Vivani Subsidiary Cortigent to Present Orion System’s - GlobeNewswire
Artificial Eye Market Size, Share, Growth | CAGR of 7.8% - Market.us
Study Links Rod Cell Evolution to Dinosaur Extinction Event - 동아사이언스
Robert Greenberg Net WorthInsider Trades and Bio as of Apr 22, 2026 - Benzinga
Science Corp.'s Prima implant enables blind patients to read - bioworld.com
Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off - GlobeNewswire
Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders - GlobeNewswire
Ocular Implants Market Size, Demand & Revenue Statistics by 2033 - Straits Research
Vivani Medical Appoints Anthony Baldor as Chief Financial Officer - GlobeNewswire
EYES Stock Price, News & Analysis - Stock Titan
Vivani to spin off neurostimulation business - MedTech Dive
Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business - Business Wire
Sight Care – Study Findings, Reviews, Ingredients and Where to Buy It - GlobeNewswire
Cortigent, Inc IPOs Tomorrow, Here's What You Need To Know - Sahm
Second Sight Medical’s Argus II Recognized by Popular Science Magazine - Medical Product Outsourcing
Bionic Eye Market to Reach US$ 524 Million by 2032 - Market.us Media
Treatment and technology: The future of retina care - Ophthalmology Times Europe
Second Sight Medical Products, Stock (EYES) Financials Data
There is no financial data for Second Sight Medical Products, (EYES). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.18%
1.44%
Cap:
|
Volume (24h):